#Mexico #Mexico City #financial results #Genomma Lab

Genomma Lab Internacional Reports First Quarter 2026 Financial Results

Genomma Lab Internacional, S.A.B. de C.V., a prominent company listed on the Mexican Stock Exchange under the ticker LAB B, recently shared its financial performance for the first quarter of 2026. The results indicate challenges stemming from a weak consumption environment in Mexico and disruptions in the U.S. Hispanic retail market, alongside a glimpse of growth in Latin America.

Key Highlights of Q1 2026

According to Marco Sparvieri, Genomma's CEO, the company experienced a like-for-like sales decline of 3.9%. This downturn is largely attributed to the sluggish consumption climate in Mexico, further impacted by continued inventory destocking in retail sectors. Despite these difficulties, a 5.3% increase in like-for-like sales was noted in Latin America, signaling positive movement where growth initiatives have begun to yield results.

In Mexico, net sales reached 4,190.6 million Mexican pesos, marking a 4.9% decrease from the previous year. The gross profit adjusted this quarter, reflecting productivity initiatives, resulted in an improved gross margin of 63.4%, an increase of 61 basis points.

However, operational challenges were evident, as the EBITDA margin fell to 22.8%, down by 96 basis points. The increased operational expenditure (OpEx) aimed at bolstering growth initiatives ahead of anticipated sales ramp-up in the latter half of 2026 contributed to this trend. Nevertheless, a 49 basis-point improvement in the net margin to 11.8% was recorded, due primarily to decreased financial expenses, which helped cushion the overall decline in operating performance.

Detailed Financial Overview

Here’s a concise summary of the company's performance in Q1 2026 compared to the same period last year:

• - Like-for-like Sales: -3.9%
• - Net Sales: 4,190.6 million pesos (down 4.9%)
• - Gross Profit: 2,657.6 million pesos (down 4.0%)
• - Operating Income: 874.4 million pesos (down 9.0%)
• - EBITDA: 956.4 million pesos (down 8.7%)
• - Net Income: 494.6 million pesos (slightly down 0.8%)

The quarterly results present a mixed picture where challenges are evident, yet opportunities exist through strategic initiatives. The management's focus remains on product innovation, expanded distribution, and effective communication strategies to maintain and grow market share amidst heightened competition.

Future Outlook

Looking ahead, Sparvieri emphasizes that while there are expected pressures on the EBITDA margin in the coming months, the company is positioning itself to leverage its strengths in the market. Continuous execution of growth strategies is anticipated to bear fruit, enhancing overall operational leverage in the latter half of the year. Despite the cyclic challenges posed by consumption weakness in Mexico, the fundamentals of Genomma Lab appear solid, paving the way for potential recovery and strengthened market positioning.

Genomma is committed to advancing its consumer-oriented marketing approach, broadening its retail distribution network, and maintaining a low-cost business model to navigate through economic fluctuations. Their agility and focus on key markets could enable them to emerge more robust in the competitive landscape.

Genomma Lab remains an important player in the pharmaceutical and personal care sectors in Mexico and continues to enhance its international presence. As they move forward, stakeholders are encouraged to track their progress through upcoming earnings calls and financial disclosures.

For further insights, Genomma will host a conference call on April 23, 2026, to discuss these results in more detail and answer questions from the investor community.